Skorpios Trust Sells 3,600,000 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) major shareholder Skorpios Trust sold 3,600,000 shares of the business’s stock in a transaction dated Wednesday, April 17th. The shares were sold at an average price of $11.60, for a total value of $41,760,000.00. Following the completion of the sale, the insider now owns 10,843,681 shares in the company, valued at $125,786,699.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Stoke Therapeutics Price Performance

Shares of STOK opened at $12.05 on Friday. The company has a market cap of $557.92 million, a PE ratio of -5.08 and a beta of 0.77. The firm has a 50-day moving average of $8.76 and a 200-day moving average of $5.99. Stoke Therapeutics, Inc. has a one year low of $3.35 and a one year high of $16.40.

Stoke Therapeutics (NASDAQ:STOK) last issued its earnings results on Monday, March 25th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.62) by $0.02. The firm had revenue of $2.80 million during the quarter, compared to analyst estimates of $3.70 million. Analysts expect that Stoke Therapeutics, Inc. will post -2.28 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Ensign Peak Advisors Inc bought a new position in Stoke Therapeutics during the first quarter worth $25,000. Point72 Hong Kong Ltd acquired a new position in Stoke Therapeutics in the 1st quarter valued at about $27,000. Great West Life Assurance Co. Can raised its holdings in Stoke Therapeutics by 46.7% in the 1st quarter. Great West Life Assurance Co. Can now owns 3,387 shares of the company’s stock valued at $28,000 after acquiring an additional 1,078 shares during the period. Dorsey & Whitney Trust CO LLC acquired a new stake in Stoke Therapeutics during the third quarter worth approximately $43,000. Finally, UBS Group AG bought a new stake in shares of Stoke Therapeutics during the third quarter worth approximately $47,000.

Analysts Set New Price Targets

Several equities research analysts have commented on the company. Wedbush boosted their target price on Stoke Therapeutics from $13.00 to $17.00 and gave the company an “outperform” rating in a research note on Tuesday, March 26th. TD Cowen raised shares of Stoke Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Tuesday, March 26th. JPMorgan Chase & Co. lifted their price target on shares of Stoke Therapeutics from $6.00 to $13.00 and gave the company a “neutral” rating in a research note on Tuesday, March 26th. Canaccord Genuity Group boosted their price target on shares of Stoke Therapeutics from $18.00 to $21.00 and gave the stock a “buy” rating in a research report on Tuesday, March 26th. Finally, HC Wainwright restated a “buy” rating and issued a $35.00 price objective on shares of Stoke Therapeutics in a report on Tuesday, March 26th. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $19.63.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.